

INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGYTM

EDITORIAL

Too Many or Too Few Hands?

PETER HESELTINE, MD

595

ORIGINAL ARTICLES

Outbreak of *Enterobacter cloacae* Related to Understaffing, Overcrowding, and Poor Hygiene Practices

STEPHAN HARBARTH, MD, MS; PHILIPPE SUDRE, MD, PhD; SASI DHARAN, MT;
MERCEDES CADENAS, MD; DIDIER PITTET, MD, MS

598

Prospective Evaluation of a Hospital Epidemiologist's Activities at a European Tertiary-Care Medical Center

CHRISTIAN RUEF, MD

604

Tuberculosis in Hemodialysis Patients in New Jersey: A Statewide Study

TERESA A. SIMON, MPH; SINDY PAUL, MD, MPH; DANIEL WARTENBERG, PhD; JEROME I. TOKARS, MD, MPH

607

Surveillance of Antimicrobial Prophylaxis for Surgical Procedures

VICTOR VAISBRUD, MD; DAVID RAVEH, MD; YECHIEL SCHLESINGER, MD; AMOS M. YINNON, MD

610

Costs and Benefits of Measures to Prevent Needlestick Injuries in a University Hospital

FRANÇOISE ROUDOT-THORAVAL, MD; OLIVIER MONTAGNE, MD; ANNETTE SCHAEFFER, MD;
MARIE-LAURE DUBREUIL-LEMAIRE, MD; DANIELE HACHARD, RN; ISABELLE DURAND-ZALESKI, MD, PhD

614

CONCISE COMMUNICATIONS

Preventing Central Venous Catheter-Related Infection in a Surgical Intensive-Care Unit

RENS BIJMA, RN, ICP; ARMAND R. GIRBES, MD, PhD; DICK J. KLEIJER, RN; JAN H. ZWAVELING, MD, PhD

618

Nosocomial Infections Caused by Multiresistant *Pseudomonas aeruginosa*

ERICO A.G. ARRUDA, MD; IVAN S. MARINHO, MD; MARCOS BOULOS, MD; SUMIKO I. SINTO, BSc; HELIO H. CALAFA F., BSc;
CAIO M. MENDES, MD; CARMEN P. OPLUSTIL, BSc; HELIO SADER, MD; CARLOS E. LEVY, MD; ANNA S. LEVIN, MD

620

Healthcare Worker Compliance With Nosocomial Tuberculosis Control Policies

PHILIP LOBUE, MD; ANTONINO CATANZARO, MD

623

Infection and Antimicrobial Use in Laparoscopic Cholecystectomy

MARYANNE MCGUCKIN, DrScEd; JUDY A. SHEA, PhD; J. SANFORD SCHWARTZ, MD

624

Bacterial Contamination of Hospital Physicians' Stethoscopes

LOUIS BERNARD, MD; ANNE KEREVEUR, MD; DOMINIQUE DURAND, RN; JEANNE GONOT, RN; FRED GOLDSTEIN, MD;
JEAN LUC MAINARDI, MD; JOSEPH ACAR, MD, PhD; JEAN CARLET, MD

626

SHEA POSITION PAPER

Prevention of Influenza in Long-Term-Care Facilities

SUZANNE F. BRADLEY, MD; THE LONG-TERM-CARE COMMITTEE OF
THE SOCIETY FOR HEALTHCARE EPIDEMIOLOGY OF AMERICA

629

Continued inside.

Are You Doing All You Can to Stop Methicillin-Resistant *Staphylococcus aureus* Outbreaks Where They Originate...

The Nares

- *Bactroban* Nasal is indicated for eradication of nasal colonization with methicillin-resistant *S. aureus* (MRSA) in adult patients and healthcare workers as part of a comprehensive infection control program to reduce the risk of infection among high-risk patients during MRSA outbreaks.¹
- In a hospital study, *Bactroban* Nasal contributed to a dramatic reduction in MRSA infections and vancomycin costs during an outbreak.²
- Excellent safety profile¹

Single-use tube
(actual size)



Please see brief summary of prescribing information on adjacent page.

References: 1. Bactroban® Nasal prescribing information, 1995. 2. Reagan DR, Dula RT, Palmer BH, et al. Control of MRSA in a VAMC with limited resources. Prog Abstr 31st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, U.S.A., Sept. 29-Oct. 2, 1991, p 104.

SB SmithKline Beecham
Pharmaceuticals

Bactroban
Nasal mupirocin
calcium

2% ointment for intranasal use

BACTROBAN® NASAL (mupirocin calcium ointment), 2%
Brief summary. For complete prescribing information, see package insert.

INDICATIONS AND USAGE

Bactroban Nasal is indicated for eradication of nasal colonization with methicillin-resistant *Staphylococcus aureus* in adult patients and health care workers as part of a comprehensive infection control program to reduce the risk of infection among patients at high risk of methicillin-resistant *S. aureus* infection during institutional outbreaks of infections with this pathogen.

NOTE:

- (1) There are insufficient data at this time to establish that this product is safe and effective as part of an intervention program to prevent autoinfection of high-risk patients from their own nasal colonization with *S. aureus*.
- (2) There are insufficient data at this time to recommend use of *Bactroban* Nasal for general prophylaxis of any infection in any patient population.
- (3) Greater than 90% of subjects/patients in clinical trials had eradication of nasal colonization 2 to 4 days after therapy was completed. Approximately 30% recolonization was reported in one domestic study within 4 weeks after completion of therapy. These eradication rates were clinically and statistically superior to those reported in subjects/patients in the vehicle-treated arms of the adequate and well-controlled studies. Those treated with vehicle had eradication rates of 5% to 30% at 2 to 4 days post-therapy with 85% to 100% recolonization within 4 weeks.

CONTRAINDICATIONS

Bactroban Nasal is contraindicated in patients with known hypersensitivity to any of the constituents of the product.

WARNINGS

AVOID CONTACT WITH THE EYES. Application of *Bactroban* Nasal to the eye under testing conditions has caused severe symptoms such as burning and tearing. These symptoms resolved within days to weeks after discontinuation of the ointment.

In the event of a sensitization or severe local irritation from *Bactroban* Nasal, usage should be discontinued.

PRECAUTIONS

General: As with other antibacterial products, prolonged use may result in overgrowth of nonsusceptible microorganisms, including fungi. (See DOSAGE AND ADMINISTRATION in complete prescribing information.)

Information for Patients: Patients should: apply approximately one-half of the ointment from the single-use tube directly into one nostril and the other half into the other nostril; avoid contact of the medication with the eyes; discard the tube after using; press the sides of the nose together and gently massage after application to spread the ointment throughout the inside of the nostrils; and discontinue using *Bactroban* Nasal and call a health care practitioner if sensitization or severe local irritation occurs.

Drug Interactions: The effect of the concurrent application of intranasal mupirocin calcium and other intranasal products has not been studied. Do not apply mupirocin calcium ointment, 2% concurrently with any other intranasal products.

Carcinogenesis, Mutagenesis, Impairment of Fertility: Long-term studies in animals to evaluate carcinogenic potential of mupirocin calcium have not been conducted. Results of the following studies performed with mupirocin calcium or mupirocin sodium *in vitro* and *in vivo* did not indicate a potential for mutagenicity: rat primary hepatocyte unscheduled DNA synthesis, sediment analysis for DNA strand breaks, *Salmonella* reversion test (Ames), *Escherichia coli* mutation assay, metaphase analysis of human lymphocytes, mouse lymphoma assay, and bone marrow micronuclei assay in mice. Reproduction studies were performed in rats with mupirocin administered subcutaneously at doses up to 40 times the human intranasal dose (approximately 20 mg mupirocin per day) on a mg/m² basis and revealed no evidence of impaired fertility from mupirocin sodium.

Pregnancy: Teratogenic Effects. Pregnancy Category B. Reproduction studies have been performed in rats and rabbits with mupirocin administered subcutaneously at doses up to 65 and 130 times, respectively, the human intranasal dose (approximately 20 mg mupirocin per day) on a mg/m² basis and revealed no evidence of harm to the fetus due to mupirocin. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.

Nursing Mothers: It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, exercise caution when *Bactroban* Nasal is administered to a nursing woman.

Pediatric Use: Safety in children under the age of 12 years has not been established. (See CLINICAL PHARMACOLOGY in complete prescribing information.)

ADVERSE REACTIONS

Clinical Trials: In clinical trials, 210 domestic and 2,130 foreign adult subjects/patients received *Bactroban* Nasal ointment. Less than 1% of domestic or foreign subjects and patients in clinical trials were withdrawn due to adverse events. In domestic clinical trials, 17% (36/210) of adults treated with *Bactroban* Nasal ointment reported adverse events thought to be at least possibly drug-related. The incidence of adverse events thought to be at least possibly drug-related that were reported in at least 1% of adults enrolled in domestic clinical trials were as follows: headache, 9%; rhinitis, 6%; respiratory disorder, including upper respiratory tract congestion, 5%; pharyngitis, 4%; taste perversion, 3%; burning/stinging, 2%; cough, 2%; and pruritus, 1%.

The following events thought possibly drug-related were reported in less than 1% of adults enrolled in domestic clinical trials: blepharitis, diarrhea, dry mouth, ear pain, epistaxis, nausea and rash. All adequate and well-controlled clinical trials have been performed using *Bactroban* Nasal ointment, 2% in one arm and the vehicle ointment in the other arm of the study.

OVERDOSAGE

Following single or repeated intranasal applications of *Bactroban* Nasal to adults, no evidence for systemic absorption of mupirocin was obtained.

Manufactured by **DPT Laboratories, Inc.**, San Antonio, TX 78215

Distributed by **SmithKline Beecham Pharmaceuticals**, Philadelphia, PA 19101

BN:L1

UWHealth
University of Wisconsin
Hospital and Clinics

INFECTION CONTROL SURVEILLANCE PRACTITIONER

The University of Wisconsin Hospital & Clinics (UWHC), a leading academic medical center, has a rare opportunity for an experienced Infection Control Practitioner. As part of our Infection Control team, you will work closely with UWHC medical faculty and department heads to implement a cutting-edge infection control program and to develop new patient care protocols and guidelines. You will also have major responsibilities for institution-wide surveillance of nosocomial infections and producing surveillance reports.

To qualify, you must have a Bachelor's degree in an appropriate healthcare field, such as Nursing, Microbiology, Medical Technology, Epidemiology or Preventive Medicine, and at least 5 years of clinical healthcare experience relevant to infection control. Certification in infection control is preferred. If you are the candidate we seek, a competitive salary, an excellent benefits package and great opportunity await you in our top-rated facility and city.

To apply, please send a resume and cover letter to:

University of Wisconsin Hospital and Clinics
Human Resources Dept. - Box KS
600 Highland Ave.
Madison, WI 53792
Or Fax at (608) 263-5778

MEDICAL EPIDEMIOLOGIST

Develop and direct all aspects of hospital epidemiology and infection control. As a faculty member of the UW School of Medicine, may have clinical, educational and research responsibilities involving epidemiology and infectious diseases. Requires an MD or equivalent degree from a recognized institution of higher education; WA State medical license (or eligibility); Board certification or equivalent in a primary medical discipline; advanced training in discipline relevant to infection control, (e.g. Infectious disease, epidemiology, microbiology).

Applicants should submit a letter and CV to:

UW Medical Centers Employment
ICHE-U-532, Box 359715
Seattle, WA 98104
Fax: (206) 731-3060
E-mail: uwmcp@u.washington.edu
EO/AEE



UNIVERSITY OF WASHINGTON
MEDICAL CENTER

THE RESULTS ARE IN COOK SPECTRUM®


¹ R. Darouiche, I. Raad, S. Heard, J. Thornby, O. Wenker, A. Gabrielli, J. Berg, N. Khardori, H. Hanna, R. Hachem, R. Harris, and G. Mayhall for the Catheter Study Group: "A Comparison of Two Antimicrobial-Impregnated Central Venous Catheters," *New England Journal of Medicine*, Volume 340, Issue 1, (1999), 1-8.

² I. Raad, R. Darouiche, J. Dupuis, D. Abi-Said, A. Gabrielli, R. Hachem, M. Wall, R. Harris, J. Jones, A. Buzaid, C. Robertson, S. Shenaq, P. Curling, T. Burke, C. Ericsson, Texas Medical Center Catheter Study Group: "Central Venous Catheters Coated with Minocycline and Rifampin for the Prevention of Catheter-Related Colonization and Bloodstream Infections: A Randomized, Double-Blind Trial," *Annals of Internal Medicine*, 127 (1997), 267-274.

³ D. Pittet, R. Wenzel: "Nosocomial Bloodstream Infections in the Critically Ill, Letter to the Editor," *Journal of the American Medical Association*, 272 (1994), 1819-1820.

To learn how Cook Spectrum® can reduce infection rates in vascular access patients and significantly lower treatment costs, contact your COOK CRITICAL CARE representative. Or call COOK at 1-800 457-4500.

An extensive new study just published in *The New England Journal of Medicine* concludes that catheters impregnated with minocycline and rifampin are **twelve times less likely** to cause bloodstream infections than catheters impregnate with chlorhexidine and silver sulfadiazine.¹



Central venous catheters are vital to patient care, but they are also the leading cause of primary nosocomial bloodstream infection.²

A single episode of catheter-related septicemia can cost up to \$28,000 to treat (and an extra 6.5 days in the ICU).³

Cook Spectrum® antimicrobial central venous catheters are impregnated throughout their inner and outer surfaces with an effective combination of minocycline and rifampin to fight bacterial colonization and infections.

COOK®

LISTEN. UNDERSTAND. INNOVATE.

www.cookgroup.com

© COPYRIGHT COOK CRITICAL CARE 1999

INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY[®]

CONTENTS

Continued from cover

READERS' FORUM

Hospital Gangrene: The Scourge of Surgeons in the Past

JACK COHEN, MD

638

LETTERS TO THE EDITOR

Factors Associated With Tuberculin Conversion Among Staff at a University-Affiliated Hospital

MANUEL ZARZUELA-RAMÍREZ, MD, MPH; JUAN A. CÓRDOBA-DOÑA, MD, MPH; EMILIO PEREA-MILLA, MD, MPH;
ENCARNACIÓN BENÍTEZ-RODRÍGUEZ, MD, MPH; ANTONIO ESCOLAR-PUJOLAR, MD, MPH;
FERNANDO J. LÓPEZ-FERNÁNDEZ, MD, MPH

589

Risk of Hepatitis A Among Hospital Personnel in an Intermediate-Endemicity Area

JOSÉ-RAMÓN DE JUANES, MD, PhD; MARÍA-PILAR ARRAZOLA, MD, PhD; ANTONIO GONZÁLEZ, MD, PhD

590

Hepatitis B Morbidity in Municipal and Hospital Waste Collection Workers in the City of Rio de Janeiro

JOÃO ALBERTO FERREIRA, DSC, PE; ANAMARIA TESTA TAMBELLINI, DSC, MD;
CARMEM LÚCIA PESSOA DA SILVA, DSC, MD; MARIA ANGÉLICA A.M. GUIMARÃES, DSC

591

Healthcare Workers' Perceptions of Occupational Exposure

SUNITA MUTHA, MD; DONNA B. JEFFE, PhD; LYNN E. KIM, MPH; PAUL B. L'ECUYER, MD;
BRADLEY A. EVANOFF, MD, MPH; VICTORIA J. FRASER, MD

592

Tea as a Source of *Acinetobacter baumannii* Ventilator-Associated Pneumonia?

THOMAS HAUER, MD; DANIEL JONAS, MD; MARKUS DETTENKOFER, MD; FRANZ D. DASCHNER, MD

594

MEDICAL NEWS

GINA PUGLIESE, RN, MS; MARTIN S. FAVERO, PhD

641

SHEA NEWS

ANDREAS VOSS, MD, PhD

644

To view abstracts of these articles,
visit us on the Internet at <http://www.slackinc.com/general/iche>

THE PUBLICATION OF ADVERTISING IN THE JOURNAL DOES NOT CONSTITUTE ANY GUARANTEE OR ENDORSEMENT BY THE SOCIETY FOR HEALTHCARE EPIDEMIOLOGY OF AMERICA OR SLACK INCORPORATED OF THE ADVERTISED PRODUCT OR SERVICE OR OF CLAIMS MADE BY THE ADVERTISER. THE PUBLICATION OF ARTICLES AND OTHER EDITORIAL MATERIAL IN THE JOURNAL DOES NOT NECESSARILY REPRESENT THE POLICY RECOMMENDATIONS OR ENDORSEMENT BY THE SOCIETY.

PUBLISHER: Infection Control and Hospital Epidemiology (ISSN-0899-823X, Canadian GST#129780466) is published exclusively by SLACK Incorporated 12 times a year. Address: 6900 Grove Rd., Thorofare, NJ 08086. Telephone: (856) 848-1000.

SHEA: 19 Mantua Rd., Mt. Royal, NJ 08061; telephone, 856-423-0087; fax, 856-423-3420; e-mail address, sheahq@talley.com.

COPYRIGHT 1999 The Society for Healthcare Epidemiology of America, Inc., and SLACK Incorporated. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. Printed in the USA.

SUBSCRIPTIONS: Requests should be addressed to the publisher (except Japan). In Japan, contact Woodbell Incorporated, 4-22-11, Kitakasai, Edogawaku, Tokyo 134, Japan. Subscription rates in the United States and possessions: Individual: One year-\$105.00; Two years-\$143.00; Three years-\$176.00; Institutional: One year-\$128.00; Two years-\$178.00; Three years-\$228.00. Fellows: \$52.50 per year with proof of training status. Canada: \$20.00 additional each year plus 7% for Canadian Goods & Services tax; Overseas surface, \$145.00 each year; Overseas air mail, \$190.00. Single copies of current issues may be obtained for \$15.00, United States and possessions; \$20.00 all other countries.

INSTRUCTIONS TO AUTHORS: Authors may submit manuscripts prepared in accordance with the 1997 revision of the "Uniform Requirements for Manuscripts Submitted to Biomedical Journals." The Uniform Requirements has been published in several journals, including *Infect Control Hosp Epidemiol* 1997;18:457-464 and *Ann Intern Med* 1997;126:36-47. A digital version is available on our web site (<http://www.slackinc.com/general/iche/ichehome.htm>). Submit to ICHE Editorial Offices, Vanderbilt University School of Medicine, A-1131 Medical Center North, Nashville, TN 37232-2637, USA. All submissions must be accompanied by copyright form(s) signed by all authors (see January issue or our web site).

REPRINTS: All requests to reprint or use material published herein should be addressed to Karen Lambertson, SLACK Incorporated, 6900 Grove Rd., Thorofare, NJ 08086. For reprint orders and prices, contact Karen Lambertson at (856) 848-1000. Authorization to photocopy items for internal or personal use, or the internal or personal use of specific clients, is granted by SLACK Incorporated, provided that the base fee of \$1.00 per copy, plus \$15 per page is paid directly to Copyright Clearance Center, 27 Congress St., Salem, MA 01970. This consent does not extend to other kinds of copying, such as for general distribution, resale, advertising and promotional purposes, or for creating new collective works.

CHANGE OF ADDRESS: Notice should be sent to the publisher 6 weeks in advance of effective date. Include old and new addresses with zip codes. The publisher cannot accept responsibility for undelivered copies. Periodicals postage paid at Thorofare, New Jersey 08086-9447 and at additional mailing offices. POSTMASTER: Send address changes to SLACK Incorporated, 6900 Grove Rd., Thorofare, NJ 08086.

INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY is listed in Index Medicus, Current Contents-Clinical Practice, Hospital Literature Index, Cumulative Index to Nursing & Allied Health Literature, Nursing Abstracts, Laboratory Performance Information Exchange System, and RNDex Top 100.

THE SOCIETY FOR HEALTHCARE EPIDEMIOLOGY OF AMERICA

A Practical Handbook for Hospital Epidemiologists

Edited by James A. Struelens, MD
 Co-edited by Michael D. Decker, MD

Soft Cover, 448 pp, ISBN 1-55642-302-0, Order# 13020, \$65.00

- **Overarching goals and ethical principles you should adopt to guide your practice**
- **What you can do to educate yourself**
- **How to negotiate with the administration and communicate with colleagues**
- **How to develop policies and procedures**
- **How to develop a surveillance system**

<https://doi.org/10.1017/S0195941700070934> Published online by Cambridge University Press

EDITORIAL OFFICES

Vanderbilt University School of Medicine
A-1131 Medical Center North
Nashville, TN 37232-2637
(615) 343-1095; (615) 343-1882 (FAX)
Email: iche@mcmail.vanderbilt.edu

EDITOR

Michael D. Decker, MD, MPH

MANAGING EDITOR

Susan Cantrell

STATISTICAL EDITOR

Beverly G. Mellen, PhD

SENIOR ASSOCIATE EDITORS

C. Glen Mayhall, MD

Gina Pugliese, RN, MS

William Schaffner, MD

ASSOCIATE EDITORS

Donald A. Goldmann, MD

Didier Pittet, MD, MS

Andreas Widmer, MD, MS

SECTION EDITORS**Beyond Infection Control:****The New Hospital Epidemiology**

Bryan P. Simmons, MD

Stephen B. Kritchevsky, PhD

Memphis, Tennessee

Wing Hong Seto, MD

Hong Kong

Disinfection and Sterilization

William A. Rutala, PhD, MPH

Chapel Hill, North Carolina

Emerging Infectious Diseases

Larry J. Strausbaugh, MD

Portland, Oregon

Robert W. Pinner, MD

Atlanta, Georgia

From the Laboratory

Marcus Zervos, MD

Royal Oak, Michigan

Fred C. Tenover, PhD

Atlanta, Georgia

Information Management

John A. Sellick, DO

Buffalo, New York

The International Perspective

Mary D. Nettleman, MD, MS

Richmond, Virginia

Issues in Surgery

James T. Lee, MD, PhD

St. Paul, Minnesota

Medical News

Gina Pugliese, RN, MS

Chicago, Illinois

Martin S. Favero, PhD

Irvine, California

Practical Healthcare Epidemiology

Loreen A. Herwaldt, MD

Iowa City, Iowa

SHEA News

Andreas Voss, MD, PhD

Nijmegen, The Netherlands

Statistics for Hospital Epidemiology

David Birnbaum, PhD, MPH

Sidney, British Columbia, Canada

Topics in Long-Term Care

Philip W. Smith, MD

Omaha, Nebraska

Topics in Occupational Medicine

David Weber, MD, MPH

Chapel Hill, North Carolina

INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY®

EDITORIAL ADVISORY BOARD

- | | |
|--------------------------------------|---|
| Jacques F. Acar, MD | Paris, France |
| J. Wesley Alexander, MD | Cincinnati, Ohio |
| Paul Arnow, MD | Chicago, Illinois |
| Graham A.J. Ayliffe, MD | Birmingham, United Kingdom |
| Neil L. Barg, MD | Yakima, Washington |
| Elizabeth Ann Bolyard, RN, MPH, CIC | Atlanta, Georgia |
| John M. Boyce, MD | Providence, Rhode Island |
| Professor Dr. Ilja Braveny | Munich, Federal Republic of Germany |
| Christian Brun-Buisson, MD | Creteil, France |
| Charles Bryan, MD | Columbia, South Carolina |
| Donald E. Craven, MD | Boston, Massachusetts |
| Sue Crow, MSN, RN, CIC | Shreveport, Louisiana |
| Franz Daschner, MD | Freiburg, Federal Republic of Germany |
| Leigh G. Donowitz, MD | Charlottesville, Virginia |
| Charles E. Edmiston, Jr., PhD | Milwaukee, Wisconsin |
| Theodore C. Eickhoff, MD | Denver, Colorado |
| Bruce Farber, MD | Manhasset, New York |
| Victoria J. Fraser, MD | St. Louis, Missouri |
| Peter C. Fuchs, MD, PhD | Black Butte, Oregon |
| Richard A. Garibaldi, MD | Farmington, Connecticut |
| Robert Gaynes, MD | Atlanta, Georgia |
| Velvl Greene, PhD, MPH | Beer Sheva, Israel |
| David W. Gregory, MD | Nashville, Tennessee |
| David K. Henderson, MD | Bethesda, Maryland |
| Peter N.R. Heseltine, MD | Los Angeles, California |
| Karen Hoffmann, RN, CIC, MS | Chapel Hill, North Carolina |
| Marguerite McMillan Jackson, RN, PhD | San Diego, California |
| Janine Jagger, MPH, PhD | Charlottesville, Virginia |
| William R. Jarvis, MD | Atlanta, Georgia |
| Douglas S. Kernodle, MD | Nashville, Tennessee |
| Robert H. Latham, MD | Nashville, Tennessee |
| Lewis B. Lefkowitz, MD | Nashville, Tennessee |
| Hsieh-Shong Leu, MD, MSc | Taipei, Taiwan |
| Jack Levy, MD | Brussels, Belgium |
| Victor Lorian, MD | Bronx, New York |
| Dennis G. Maki, MD | Madison, Wisconsin |
| William J. Martone, MD | Bethesda, Maryland |
| Allison McGeer, MD | Toronto, Ontario, Canada |
| John E. McGowan, Jr., MD | Atlanta, Georgia |
| Jonathan L. Meakins, MD, DSc | Montreal, Quebec, Canada |
| Raf Mertens, MD | Brussels, Belgium |
| Robert R. Muder, MD | Pittsburgh, Pennsylvania |
| Joseph M. Mylotte, MD, CIC | Buffalo, New York |
| Lindsay Nicolle, MD | Winnipeg, Manitoba, Canada |
| Juhani Ojajarvi, MD | Helsinki, Finland |
| Michael T. Osterholm, PhD, MPH | Minneapolis, Minnesota |
| Jan Evans Patterson, MD | San Antonio, Texas |
| Sindy M. Paul, MD | Trenton, New Jersey |
| Michael A. Pfaller, MD | Iowa City, Iowa |
| Samuel Ponce de Leon, MD, MSc | Mexico City, Mexico |
| Isaam Raad, MD | Houston, Texas |
| Manfred L. Rotter, MD, DipBact | Vienna, Austria |
| Theodore Sacks, MD | Jerusalem, Israel |
| William E. Scheckler, MD | Madison, Wisconsin |
| Kent Sepkowitz, MD | New York City, New York |
| Denis Spelman, MD | Prahran Victoria, Australia |
| Michael L. Tapper, MD | New York, New York |
| Clyde Thornsberrry, PhD | Brentwood, Tennessee |
| Professor Leonid P. Titov | Minsk, Republic of Belarus |
| Timothy R. Townsend, MD | Millwood, Virginia |
| Antoni Trilla, MD, PhD | Barcelona, Spain |
| Professor Wang Shu-Qun | Beijing, People's Republic of China |
| J. John Weems, Jr., MD | Greenville, South Carolina |
| Robert A. Weinstein, MD | Chicago, Illinois |
| Professor Dr. W. Weuffen | Greifswald, Federal Republic of Germany |
| Sergio B. Wey, MD | São Paulo, Brazil |
| Rebecca Wurtz, MD | Evanston, Illinois |

SLACK Incorporated

6900 Grove Road
Thorofare, New Jersey 08086
(856) 848-1000

Vice President/Group Publisher

Richard N. Roash

Publisher

John C. Carter

Editorial Director

Jennifer Kilpatrick

Production Editor

Shirley P. Strunk, ELS

Assistant Editor

Eileen C. Anderer

Editorial Assistant

Aileen Schneider

Circulation Manager

Lester J. Robeson, CCCP

Production Director

Christine Malin

Production Coordinator

Joanne Patterson

Publishing Director/ Advertising

Wayne McCourt

Pharmaceutical Group Sales Director

Michael LoPresti

Advertising Sales Representative

Tina Panna

Advertising Coordinator/Product Sales

Kathy Miranda

Classified/Recruitment Sales Manager

Kathy Huntley

Classified/Recruitment Sales Representative

Kelly Wark

Mothers. Spouses. (maybe) Medical Matrix.

What do they have in common? You place your trust in them. When searching the Internet for credible medical information, you need a resource you can trust. *The Lancet* quotes that "Medical Matrix is the most comprehensive compendium of reliable medical information on the Internet."

MEDICAL MATRIX^{LLC.}

<http://www.medmatrix.org>

The largest, peer-reviewed directory to the medical Internet.

Free registration.

SHEA

**CDC Guidelines
for Surveillance
Prevention & Control
of Nosocomial
Infections**

**All In One
Single Volume
for only \$99.⁰⁰***

Plus Shipping
& Handling

Urinary Tract Infections • Surgical Wound Infections
Handwashing and Environmental Control
Hospital Personnel • HIV and HBV Exposure-
Prone Procedures • Pneumonia Tuberculosis
Vancomycin Resistance • IV Device-Related
Infections • Isolation Precautions
HIV Post-Exposure Chemoprophylaxis
HCV Post-Exposure Prophylaxis
and Index of SHEA Position Papers

Foreword by Julia S. Garner, RN, MN

To Order Call 1-800-552-0076

International Orders 414-634-0806

E-mail ETNAComm@aol.com

* SHEA Journal Subscribers mention this ad for 10% discount.
Orders outside the U.S.A., Canada, & Mexico are \$175.00 each.

SJ198



**Consumer
Information
Catalog**

www.pueblo.gsa.gov

9 out of 10 mice prefer the Consumer Information Catalog online. Just point and click your way to www.pueblo.gsa.gov and you'll find more than 250 free publications ready to read or download.

U.S. General Services Administration

NOW AVAILABLE ON CD-ROM:

INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY

1988 - 1998

Simplifying your reference library is easy, with 11 years of INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY now available on CD-ROM. As the official journal of the Society for Healthcare Epidemiology of America (SHEA), this ready reference will allow the user to quickly and easily access articles and studies from 1988-1998 that can help put current issues of epidemiology and infection control in perspective.

Easy and Convenient CD-ROM Technology

The INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY CD-ROM will take full advantage of the latest CD-ROM technology, including:

- **searchable text**
- **annual indexes organized by category, page number, subject and author**
- **convenient updates**
- **PC and Mac compatibility**

The INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY CD-ROM packs an enormous amount of information in a small space at a comparably small price! Adding 11 years of this informative journal to your library is a bargain, at special prices starting as low as \$147.

Money-Back Guarantee

The Society for Healthcare Epidemiology of America is always looking for innovative ways to keep you informed of important developments in infection control and hospital epidemiology. We are sure you will refer to the information in the INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY CD-ROM often. If you aren't satisfied, we offer a 30-day money-back guarantee.*

To order, call us at **800-257-8290** or **609-848-1000** (in NJ); or write to
INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY
6900 Grove Rd., Thorofare, NJ 08086

☐ **Yes!** Please send me the INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY CD-ROM. Enclosed is a check or money order for the amount/quantity checked below.

<input type="checkbox"/> SHEA Member:	\$147.00 ea.	Qty: _____
<input type="checkbox"/> Individual Non-Member:	\$197.00 ea.	Qty: _____
<input type="checkbox"/> Institution:	\$247.00 ea.	Qty: _____

Or bill my ☐ Visa ☐ Mastercard ☐ Amex

Acct. No. _____ Exp. date: ____/____/____

Signature: _____

Send CD-ROM to:

Name _____

Address _____

City _____ State _____ Zip _____

Phone _____ FAX _____

Send order and make check payable to:

INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY • 6900 Grove Rd. • Thorofare, NJ 08086

Or FAX your order to: (609) 853-5991

For fastest service, call today: 1-800-257-8290 or 609-848-1000 (in NJ)

<https://doi.org/10.1017/S0195941700070934> Published online by Cambridge University Press

Exp: 11/99

*If not completely satisfied with the INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY CD-ROM, just return it within 30 days and your money will be refunded.



SHEA/SANG-HA TRAINING COURSE IN INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY

**November 6-9, 1999
King Fahad National Guard Hospital
Riyadh, Saudi Arabia**

This training program is designed for those who have responsibility for hospital epidemiology and infection control programs. It is sponsored by the Society for Healthcare Epidemiology of America and the Saudia Arabian National Guard Health Affairs (SANG-HA). The course is taught by experts from the United States and the Middle East who support the pursuit of continuing education to broaden the scope of influence through new appli-

cation of epidemiological skills and continuous improvement of infection control. Topics to be addressed include patterns of transmission of nosocomial infections; risk factors for nosocomial infections; epidemic investigation; review of surveillance techniques; disinfection and sterilization; employee safety and health, and control of bloodborne pathogens; and introduction to quality-improvement challenges facing hospital epidemiologists.

For more information contact:

Ziad A. Memish, MD
Symposium Chair
E-mail: memish@ngha.med.sa
Academic Affairs
PO Box 22490
Riyadh 11426, Saudi Arabia
Fax: 966-1-252-0040
Telephone: 966-11-252-0088, ext 2329

